A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL

StatusRecruiting
PhasePhase 3
SponsorHutchmed
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 41 → 50 locationsv3
  2. Recruitment opened
    • Trial sites expanded: 0 → 41 locations
    • Start date changed from estimate of Mar 10, 2026 to Mar 20, 2026
    • Study title shortened, about 4 words
    v2
  3. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Hutchmed
23 trials monitored
See 1 trial at risk
Non-Hodgkin Lymphoma
2,026 trials monitored
See 116 trials at risk
DLBCL
710 trials monitored
See 47 trials at risk
This is a Phase III randomized, double-blind, positive controlled study to evaluate the efficacy, safety, and pharmacokinetics of HMPL-760 in combination with R-GemOx versus placebo in combination with R-GemOx in patients with R/R DLBCL.
Trial Details
NCT Number NCT07409428
Lead Sponsor Hutchmed
Conditions
(from sponsor)		 Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Related terms Lymphoma, Large B-Cell, Diffuse
Enrollment 240 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov